{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:59:05Z","timestamp":1790499545798,"version":"4.1.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02571","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T23:26:36Z","timestamp":1572996396000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus"],"prefix":"10.3389","volume":"10","author":[{"given":"Rebecca L.","family":"Krain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn J.","family":"Kushner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Tarazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca G.","family":"Gaffney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea C.","family":"Yeguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle E.","family":"Zamalin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee S.","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of disease: pemphigus and bullous pemphigoid","volume":"11","author":"Hammers","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat Rev Dis Prim."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1007\/s11136-015-0965-z","article-title":"Reliability of the autoimmune bullous disease quality of life (ABQOL) questionnaire in the USA","volume":"24","author":"Sebaratnam","year":"2015","journal-title":"Qual Life Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jaad.2008.09.014","article-title":"Quality-of-life assessment in patients with pemphigus using a minimum set of evaluation tools","volume":"60","author":"Paradisi","year":"2009","journal-title":"J Am Acad Dermatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/j.1365-2230.2011.04282.x","article-title":"Quality of life in patients with pemphigus receiving adjuvant therapy","volume":"37","author":"Paradisi","year":"2012","journal-title":"Clin Exp Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12955-017-0594-z","article-title":"Reliability and validity of the Chinese version of the autoimmune bullous disease quality of life (ABQOL) questionnaire","volume":"15","author":"Yang","year":"2017","journal-title":"Health Qual Life Outcomes."},{"key":"B7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1610-0387.2005.05722.x","article-title":"Significant decrease in quality of life in patients with pemphigus vulgaris. Results from the German Bullous Skin Disease (BSD) Study Group","volume":"3","author":"Mayrshofer","year":"2005","journal-title":"J Dtsch Dermatol Ges"},{"key":"B8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0151-9638(05)79276-0","article-title":"Quality of life and pemphigus","volume":"132","author":"Terrab","year":"2005","journal-title":"Ann Dermatol Venereol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.5021\/ad.2015.27.5.492","article-title":"Quality of life assessment in korean patients with Pemphigus","volume":"27","author":"Sung","year":"2015","journal-title":"Ann Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.det.2011.03.009","article-title":"Pemphigus and quality of life","volume":"29","author":"Chee","year":"2011","journal-title":"Dermatol Clin"},{"key":"B11","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.jid.2017.02.406","article-title":"Quality of life in autoimmune blistering diseases (AIBD)","volume":"137","author":"Pena","year":"2017","journal-title":"J Invest Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1346-8138.2011.01382.x","article-title":"Quality of life and psychological status of patients with pemphigus vulgaris using dermatology life quality index and general health questionnaires","volume":"39","author":"Ghodsi","year":"2012","journal-title":"J Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clindermatol.2011.03.016","article-title":"Quality of life in patients with bullous dermatoses","volume":"30","author":"Sebaratnam","year":"2012","journal-title":"Clin Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/bjd.14562","article-title":"Quantifying disease extent in pemphigus","volume":"175","author":"Payne","year":"2016","journal-title":"Br J Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1023\/A:1008996223999","article-title":"Recommendations on health-related quality of life research to support labeling and promotional claims in the United States","volume":"9","author":"Revicki","year":"2000","journal-title":"Qual Life Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1111\/bjd.13848","article-title":"Health-related quality of life and its determinants in pemphigus: a systematic review and meta-analysis","volume":"173","author":"Rencz","year":"2015","journal-title":"Br J Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/bjd.14405","article-title":"Calculation of cut-off values based on the autoimmune bullous skin disorder intensity score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus","volume":"175","author":"Boulard","year":"2016","journal-title":"Br J Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijwd.2016.10.003","article-title":"Validation studies of outcome measures in pemphigus","volume":"2","author":"Hanna","year":"2016","journal-title":"Int J Womens Dermatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1684\/ejd.2007.0090","article-title":"Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus","volume":"17","author":"Pf\u00fctze","year":"2007","journal-title":"Eur J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1001\/jamadermatol.2013.8175","article-title":"Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score","volume":"150","author":"Rahbar","year":"2014","journal-title":"JAMA Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jid.2018.04.042","article-title":"Large international validation of ABSIS and PDAI pemphigus severity scores","volume":"139","author":"H\u00e9bert","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1038\/jid.2009.72","article-title":"Reliability and convergent validity of two outcome instruments for pemphigus","volume":"129","author":"Rosenbach","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jaad.2004.12.015","article-title":"Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life","volume":"54","author":"Hundley","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","article-title":"Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial","volume":"49","author":"Heald","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.clindermatol.2011.03.017","article-title":"Severity score indexes for blistering diseases","volume":"30","author":"Daniel","year":"2012","journal-title":"Clin Dermatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"B28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1087-0024.2004.09113.x","article-title":"Finlay, 10 years experience of the dermatology life quality index (DLQI)","volume":"9","author":"Lewis","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"key":"B29","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jama.272.8.619","article-title":"A critical appraisal of the quality of quality-of-life measurements","volume":"272","author":"Gill","year":"1994","journal-title":"JAMA"},{"key":"B30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000051809","article-title":"Further evidence of the validity and reliability of the Skindex-29: an Italian study on 2,242 dermatological outpatients","volume":"204","author":"Abeni","year":"2002","journal-title":"Dermatology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1038\/sj.jid.5701176","article-title":"Dermatology quality of life instruments: sorting out the quagmire","volume":"127","author":"Chen","year":"2007","journal-title":"J Invest Dermatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.2147\/COPD.S100204","article-title":"Systematic review of the association between exercise tests and patient-reported outcomes in patients with chronic obstructive pulmonary disease","volume":"12","author":"Punekar","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1532-5415.2008.02150.x","article-title":"The co-occurrence of chronic diseases and geriatric syndromes: the health and retirement study","volume":"57","author":"Lee","year":"2009","journal-title":"J Am Geriatr Soc"},{"key":"B34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/1523-1747.ep12285650","article-title":"Convergent and discriminant validity of a generic and a disease-specific instrument to measure quality of life in patients with skin disease","volume":"108","author":"Chren","year":"1997","journal-title":"J Invest Dermatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/S0735-6757(00)90124-4","article-title":"Autoimmune blistering skin diseases","volume":"18","author":"Cotell","year":"2000","journal-title":"Am J Emerg Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/1346-8138.12649","article-title":"Grading criteria for disease severity by pemphigus disease area index","volume":"41","author":"Shimizu","year":"2014","journal-title":"J Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02571\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T23:26:37Z","timestamp":1572996397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02571\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2019.02571"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02571","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,6]]},"article-number":"2571"}}